Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer : the KEYNOTE-062 phase 3 randomized clinical trial

Simple item page
dc.contributor.authorShitara, K.
dc.contributor.authorVan Cutsem, E.
dc.contributor.authorBang, Y. J.
dc.contributor.authorFuchs, C.
dc.contributor.authorWyrwicz, L.
dc.contributor.authorLee, K.W.
dc.contributor.authorKudaba, I.
dc.contributor.authorGarrido S., Marcelo
dc.contributor.authorChung, H. C.
dc.contributor.authorLee, J.
dc.contributor.authorCastro, H. R.
dc.contributor.authorMansoor, W.
dc.contributor.authorBraghiroli, M. I.
dc.contributor.authorKaraseva, N.
dc.contributor.authorCaglevic, C.
dc.contributor.authorVillanueva, L.
dc.contributor.authorGoekkurt, E.
dc.contributor.authorSatake, H.
dc.contributor.authorEnzinger, P.
dc.contributor.authorAlsina, M.
dc.contributor.authorBenson, A.
dc.contributor.authorChao, J.
dc.contributor.authorKo, A. H.
dc.contributor.authorWainberg, Z. A.
dc.contributor.authorKher, U.
dc.contributor.authorShah, S.
dc.contributor.authorKang, S. P.
dc.contributor.authorTabernero, J.
dc.date.accessioned2021-08-13T20:26:22Z
dc.date.available2021-08-13T20:26:22Z
dc.date.issued2020
dc.fechaingreso.objetodigital2024-04-19
dc.fuente.origenConveris
dc.identifier.doi10.1001/jamaoncol.2020.3370
dc.identifier.doi10.1001/jamaoncol.2020.3370
dc.identifier.eissn2374-2445
dc.identifier.issn2374-2437
dc.identifier.pubmedid32880601
dc.identifier.scopusid2-s2.0-85091456614
dc.identifier.urihttps://doi.org/10.1001/jamaoncol.2020.3370
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/61904
dc.information.autorucEscuela de Medicina ; Garrido Salvo, Marcelo Adán ; 0000-0001-8905-8986 ; 7260
dc.language.isoen
dc.nota.accesoContenido parcial
dc.revistaJAMA Oncologyes_ES
dc.rightsacceso restringido
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.otherNeoplasmas estomacaleses_ES
dc.subject.otherUnión esofagogástricaes_ES
dc.subject.otherAnticuerpos monoclonaleses_ES
dc.subject.otherCáncer gástricoes_ES
dc.titleEfficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer : the KEYNOTE-062 phase 3 randomized clinical triales_ES
dc.typeartículo
sipa.codpersvinculados7260
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer The KEYNOTE-062 Phase 3 Randomized.pdf
Size:
196.11 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas